The search for treatments for neurodegenerative diseases is a major concern in light of
today's aging population and an increasing burden on individuals, families, and society …

Abstract Sp1 (specificity protein 1) is a well-known member of a family of transcription factors
that also includes Sp2, Sp3 and Sp4, which are implicated in an ample variety of essential …

Metformin, a drug widely used for treating diabetes, can prolong the lifespan in several
species. Metformin also has the promise to slow down age‐related cognitive impairment …

There is growing evidence that metabolic alterations play an important role in cancer
development and progression. The metabolism of cancer cells is reprogrammed in order to …

Purpose: We aimed to assess the safety and efficacy of metformin for treating patients with
metastatic pancreatic cancer and to identify endocrine and metabolic phenotypic features or …

Currently, there are no effective preventive strategies for pancreatic cancer. Obesity has
been increasingly recognized as a strong but modifiable risk factor of pancreatic cancer. In …

Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer-associated mortality worldwide with an overall five-year survival rate less than 7 …

Aim Emerging evidence from epidemiologic studies and basic science suggests a potential
antitumour effect of metformin. However, whether metformin improves survival in cancer …

Background Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with
a dismal prognosis for most patients. Fibrosis and inflammation are hallmarks of tumor …

The antidiabetic drug metformin exhibits both chemopreventive and chemotherapeutic
activity for multiple cancers including pancreatic cancer; however, the underlying …